The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

These jobs will propel the province towards being a global leader in biomanufacturing and life sciences. MISSISSAUGA, ON, Nov ...

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...

Executive Vice-President of Diagnostics, Africa, at Roche Diagnostics, Dr. Allan Pamba, has urged action against diabetes. He said November is World Diabetes Awareness month, noting non-communicable ...

Ontario is a prime location for domestic and international biomanufacturers looking to invest and bring their innovative ideas from lab to market,” said Vic Fedeli, Minister of Economic Development, ...

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

The best La Roche-Posay skincare products, including anti-aging options and picks for acne-prone, oily, dry, mature, ...

Roche Holding AG (RHHVF) Company Description: Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The ...

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

Discover what it takes to become a fleet champion through the real-world achievements of nominated and award-winning industry ...